BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Overview
NASDAQ:BCRX - US09058V1035 - Common Stock
BCRX Key Statistics, Chart & Performance
The current stock price of BCRX is 8.58 USD. In the past month the price increased by 6.06%. In the past year, price decreased by -1.27%.
BCRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.68 | 368.08B | ||
| AMGN | AMGEN INC | 13.28 | 155.90B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 99.27B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 62.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.14B | ||
| ARGX | ARGENX SE - ADR | 76.39 | 43.34B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.24 | 36.72B | ||
| INSM | INSMED INC | N/A | 27.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.19B | ||
| NTRA | NATERA INC | N/A | 22.74B | ||
| BIIB | BIOGEN INC | 8.54 | 20.04B |
Related stock screener links
About BCRX
Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Company Info
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703 US
CEO: Jon P. Stonehouse
Employees: 580
Phone: 19198591302
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
What is the stock price of BIOCRYST PHARMACEUTICALS INC today?
The current stock price of BCRX is 8.58 USD. The price increased by 2.26% in the last trading session.
What is the ticker symbol for BIOCRYST PHARMACEUTICALS INC stock?
The exchange symbol of BIOCRYST PHARMACEUTICALS INC is BCRX and it is listed on the Nasdaq exchange.
On which exchange is BCRX stock listed?
BCRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOCRYST PHARMACEUTICALS INC stock?
18 analysts have analysed BCRX and the average price target is 17.99 USD. This implies a price increase of 109.66% is expected in the next year compared to the current price of 8.58. Check the BIOCRYST PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOCRYST PHARMACEUTICALS INC worth?
BIOCRYST PHARMACEUTICALS INC (BCRX) has a market capitalization of 1.80B USD. This makes BCRX a Small Cap stock.
How many employees does BIOCRYST PHARMACEUTICALS INC have?
BIOCRYST PHARMACEUTICALS INC (BCRX) currently has 580 employees.
What are the support and resistance levels for BIOCRYST PHARMACEUTICALS INC (BCRX) stock?
BIOCRYST PHARMACEUTICALS INC (BCRX) has a support level at 8.43 and a resistance level at 8.59. Check the full technical report for a detailed analysis of BCRX support and resistance levels.
Is BIOCRYST PHARMACEUTICALS INC (BCRX) expected to grow?
The Revenue of BIOCRYST PHARMACEUTICALS INC (BCRX) is expected to grow by 38.88% in the next year. Check the estimates tab for more information on the BCRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOCRYST PHARMACEUTICALS INC (BCRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCRX, evaluating the profitability, health, valuation and growth aspects
- BIOCRYST PHARMACEUTICALS INC (BCRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOCRYST PHARMACEUTICALS INC (BCRX) Sales and EPS estimates to see what analysts future expectations are.
- BIOCRYST PHARMACEUTICALS INC (BCRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOCRYST PHARMACEUTICALS INC (BCRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Chart to make your own analysis
- BIOCRYST PHARMACEUTICALS INC (BCRX) Latest news and press-releases to stay up to date.
Does BIOCRYST PHARMACEUTICALS INC (BCRX) stock pay dividends?
BCRX does not pay a dividend.
When does BIOCRYST PHARMACEUTICALS INC (BCRX) report earnings?
BIOCRYST PHARMACEUTICALS INC (BCRX) will report earnings on 2025-11-03, before the market open.
What is the Price/Earnings (PE) ratio of BIOCRYST PHARMACEUTICALS INC (BCRX)?
BIOCRYST PHARMACEUTICALS INC (BCRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.16).
What is the Short Interest ratio of BIOCRYST PHARMACEUTICALS INC (BCRX) stock?
The outstanding short interest for BIOCRYST PHARMACEUTICALS INC (BCRX) is 12.76% of its float. Check the ownership tab for more information on the BCRX short interest.
BCRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCRX. When comparing the yearly performance of all stocks, BCRX is a bad performer in the overall market: 84.2% of all stocks are doing better.
BCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BCRX. Both the profitability and the financial health of BCRX get a neutral evaluation. Nothing too spectacular is happening here.
BCRX Financial Highlights
Over the last trailing twelve months BCRX reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 77.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCRX Forecast & Estimates
18 analysts have analysed BCRX and the average price target is 17.99 USD. This implies a price increase of 109.66% is expected in the next year compared to the current price of 8.58.
For the next year, analysts expect an EPS growth of 120.37% and a revenue growth 38.88% for BCRX